Clinical Trials Directory

Trials / Sponsors / Eidos Therapeutics, a BridgeBio company

Eidos Therapeutics, a BridgeBio company

Industry · 10 registered clinical trials — 2 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingTo Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (
Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy
Phase 32025-11-01
RecruitingAcoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers
Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
Phase 32025-05-12
Active Not RecruitingOpen-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Amyloid Cardiomyopathy, Transthyretin-Related
Phase 32021-10-27
WithdrawnEfficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Phase 32021-09-08
CompletedA Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Su
Amyloidosis
Phase 12021-03-28
WithdrawnEfficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Phase 32020-10-21
CompletedEfficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
Phase 32019-03-19
Active Not RecruitingOpen-Label Study of AG10 in Patients with Cardiomyopathy
Amyloid Cardiomyopathy
Phase 22018-08-08
CompletedStudy of AG10 in Amyloid Cardiomyopathy
Familial ATTR-CM (ATTRm-CM, or FAC), Wild-type ATTR-CM (ATTRwt-CM)
Phase 22018-04-27
CompletedSingle and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10
Amyloid Cardiomyopathy, Transthyretin-Related
Phase 12017-09-11